



16 December 2015, Melbourne, Australia: Opthea Limited (ASX:OPT) has featured in the ASX CEO Sessions, part of the ASX Evolve program.

Dr Megan Baldwin, CEO & Managing Director of Opthea Limited, presented Opthea's OPT-302 program for wet AMD to an audience of retail and institutional investors in Sydney.

To view the presentation, please click on the link:

http://www.finnewsnetwork.com.au/Presentations/CEO_Sessions_2016/Feb_Syd/Opthea.html

To view the interview, please click on the link:

<https://content.jwplatform.com/previews/nOGaHuS4-d54En2nY>

Company & Media Enquiries:

Megan Baldwin, PhD
CEO & Managing Director
Opthea Limited
Tel: +61 (0) 3 9826 0399
Megan.baldwin@opthea.com

Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399
info@opthea.com
www.opthea.com

About Opthea Limited

Opthea (ASX:OPT; OTCQX:CKDXY) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Opthea's internal product development programs are primarily focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for 'back of the eye' disease such as wet age-related macular degeneration (wet AMD).